[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Krystal Biotech Inc (KRYS)

Krystal Biotech Inc (KRYS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,026,020
  • Shares Outstanding, K 29,436
  • Annual Sales, $ 389,130 K
  • Annual Income, $ 204,830 K
  • EBIT $ 161 M
  • EBITDA $ 168 M
  • 60-Month Beta 0.54
  • Price/Sales 20.92
  • Price/Cash Flow 37.93
  • Price/Book 6.57

Options Overview Details

View History
  • Implied Volatility 53.57% (-1.41%)
  • Historical Volatility 31.04%
  • IV Percentile 74%
  • IV Rank 74.33%
  • IV High 59.89% on 04/23/25
  • IV Low 35.27% on 12/05/25
  • Expected Move (DTE 23) 28.27 (10.25%)
  • Put/Call Vol Ratio 31.66
  • Today's Volume 1,045
  • Volume Avg (30-Day) 272
  • Put/Call OI Ratio 0.36
  • Today's Open Interest 4,123
  • Open Int (30-Day) 4,735
  • Expected Range 247.67 to 304.21

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $1.49
  • Number of Estimates 4
  • High Estimate $1.62
  • Low Estimate $1.30
  • Prior Year $1.20
  • Growth Rate Est. (year over year) +24.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
242.00 +14.02%
on 03/31/26
278.86 -1.05%
on 04/20/26
+24.26 (+9.64%)
since 03/20/26
3-Month
242.00 +14.02%
on 03/31/26
298.30 -7.50%
on 02/17/26
-13.18 (-4.56%)
since 01/22/26
52-Week
122.80 +124.71%
on 05/23/25
298.30 -7.50%
on 02/17/26
+107.14 (+63.47%)
since 04/22/25

Most Recent Stories

More News
Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026

PITTSBURGH, April 21, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its first quarter 2026 financial results on Monday, May...

KRYS : 275.94 (+1.20%)
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services

Ms. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (Nasdaq: KRYS), where she helped lead the U.S. launch of VYJUVEK®, supporting its...

KRYS : 275.94 (+1.20%)
PVLA : 130.64 (-0.01%)
Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference

PITTSBURGH, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the TD Cowen 46th Annual Health Care Conference...

KRYS : 275.94 (+1.20%)
Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results

$107.1 million in 4Q VYJUVEK revenue and $730.3 million since U.S. launch FDA granted RMAT to KB707 for the treatment of advanced NSCLC and Fast Track Designation to KB111 for the treatment...

KRYS : 275.94 (+1.20%)
Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

PITTSBURGH, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its fourth quarter and full year 2025 financial results...

KRYS : 275.94 (+1.20%)
Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer

PITTSBURGH, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) granted Regenerative...

KRYS : 275.94 (+1.20%)
Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Preliminary 4Q 2025 VYJUVEK net revenue of $106 million to $107 million Robust clinical pipeline with multibillion dollar opportunities and strong balance sheet for sustained growth PITTSBURGH,...

KRYS : 275.94 (+1.20%)
Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis

Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations KB407 transduction confirmed in all six patients with successful bronchoscopies irrespective...

KRYS : 275.94 (+1.20%)
Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis

PITTSBURGH, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that it will host an investor conference call and webcast tomorrow, Thursday,...

KRYS : 275.94 (+1.20%)
Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference

PITTSBURGH, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 44 th Annual J.P. Morgan Healthcare...

KRYS : 275.94 (+1.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States.

See More

Key Turning Points

3rd Resistance Point 285.65
2nd Resistance Point 281.86
1st Resistance Point 278.90
Last Price 275.94
1st Support Level 272.14
2nd Support Level 268.35
3rd Support Level 265.39

See More

52-Week High 298.30
Last Price 275.94
Fibonacci 61.8% 231.26
Fibonacci 50% 210.55
Fibonacci 38.2% 189.84
52-Week Low 122.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.